Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Leslie Norwalk sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Monday, December 15th. The stock was sold at an average price of $152.23, for a total transaction of $761,150.00. Following the transaction, the director owned 7,429 shares in the company, valued at approximately $1,130,916.67. This trade represents a 40.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $142.51 on Thursday. The stock has a market capitalization of $14.21 billion, a PE ratio of 34.02, a PEG ratio of 0.98 and a beta of 0.27. The business’s 50 day simple moving average is $145.93 and its 200 day simple moving average is $137.76. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm had revenue of $794.90 million for the quarter, compared to the consensus estimate of $746.61 million. During the same quarter in the previous year, the company earned $1.81 EPS. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Citigroup upped their target price on Neurocrine Biosciences from $175.00 to $203.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada raised their price target on shares of Neurocrine Biosciences from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. HC Wainwright increased their target price on shares of Neurocrine Biosciences from $168.00 to $198.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler upped their price target on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Finally, TD Cowen raised their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.76.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. American Century Companies Inc. raised its position in shares of Neurocrine Biosciences by 106.6% in the first quarter. American Century Companies Inc. now owns 191,182 shares of the company’s stock worth $21,145,000 after buying an additional 98,659 shares in the last quarter. Korea Investment CORP boosted its position in shares of Neurocrine Biosciences by 42.4% during the 1st quarter. Korea Investment CORP now owns 86,989 shares of the company’s stock valued at $9,621,000 after acquiring an additional 25,900 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Neurocrine Biosciences by 44.0% during the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock worth $232,037,000 after purchasing an additional 640,556 shares in the last quarter. Hsbc Holdings PLC lifted its position in Neurocrine Biosciences by 14.4% during the first quarter. Hsbc Holdings PLC now owns 243,035 shares of the company’s stock valued at $26,887,000 after purchasing an additional 30,681 shares during the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Neurocrine Biosciences by 2.6% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 143,369 shares of the company’s stock worth $15,857,000 after buying an additional 3,699 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.